NBIX
NASDAQ · Biotechnology
Neurocrine Biosciences Inc
$163.41
+3.59 (+2.25%)
Financial Highlights (FY 2026)
Revenue
2.84B
Net Income
475.97M
Gross Margin
98.2%
Profit Margin
16.7%
Rev Growth
+24.3%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 98.2% | 98.2% | 30.1% | 30.1% |
| Operating Margin | 21.6% | 19.5% | 12.0% | 12.6% |
| Profit Margin | 16.7% | 15.9% | 9.0% | 10.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.84B | 2.29B | 5.53B | 5.58B |
| Gross Profit | 2.79B | 2.25B | 1.67B | 1.68B |
| Operating Income | 615.60M | 445.66M | 665.45M | 705.45M |
| Net Income | 475.97M | 344.57M | 497.45M | 570.29M |
| Gross Margin | 98.2% | 98.2% | 30.1% | 30.1% |
| Operating Margin | 21.6% | 19.5% | 12.0% | 12.6% |
| Profit Margin | 16.7% | 15.9% | 9.0% | 10.2% |
| Rev Growth | +24.3% | +24.3% | -8.7% | -7.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 3.03B | 2.43B |
| Total Equity | — | — | 6.26B | 6.50B |
| D/E Ratio | — | — | 0.48 | 0.37 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 641.55M | 490.25M | 909.27M | 972.70M |
| Free Cash Flow | — | — | 422.12M | 662.00M |